Non-invasive diagnosis of non-alcoholic fatty liver disease

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 65, Issue 3, Pages (September 2016)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Volume 41, Issue 6, Pages (December 2004)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Abnormal Liver Tests and Fatty Liver on Ultrasound
Thrombocytopenia With Abnormal Liver Function Tests
Treatment of NAFLD with diet, physical activity and exercise
Primary prevention of variceal haemorrhage: A pharmacological approach
Volume 61, Issue 6, Pages (December 2014)
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Uncoupling proteins and non-alcoholic fatty liver disease
Figure 1 Proposed algorithm for the management
Marcus-Alexander Wörns, Peter Robert Galle  Journal of Hepatology 
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
The evidence supports a viral aetiology for primary biliary cirrhosis
Volume 69, Issue 1, Pages (July 2018)
Living donor liver transplantation: is the hype over?
Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients 
Volume 149, Issue 2, Pages (August 2015)
Volume 69, Issue 2, Pages (August 2018)
Autoimmune hepatitis Journal of Hepatology
Volume 44, Pages S19-S24 (January 2006)
Stephen A. Harrison, MD, FACP  Clinical Gastroenterology and Hepatology 
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
Autoimmune hepatitis: A life-long disease
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Abstracts from Around the World
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Trends in the management and burden of alcoholic liver disease
Volume 54, Issue 5, Pages (May 2011)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
When the journey from obesity to cirrhosis takes an early start
Severe Constipation Clinical Gastroenterology and Hepatology
EASL Clinical Practice Guidelines: Wilson’s disease
Pierre Nahon, Jessica Zucman-Rossi  Journal of Hepatology 
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Abnormal Liver Tests and Fatty Liver on Ultrasound
The heart in liver transplantation
Volume 69, Issue 3, Pages (September 2018)
The changing role of beta-blocker therapy in patients with cirrhosis
Volume 57, Issue 5, Pages (November 2012)
Hepatology may have problems with putative surrogate outcome measures
Volume 69, Issue 5, Pages (November 2018)
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Paul C. Adams, James C. Barton  Journal of Hepatology 
Non-invasive evaluation of liver fibrosis using transient elastography
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 64, Issue 6, Pages (June 2016)
Volume 63, Issue 1, Pages (July 2015)
Chronic hepatitis B in children and adolescents
Thrombocytopenia With Abnormal Liver Function Tests
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba  Gastroenterology 
Volume 60, Issue 6, Pages (June 2014)
Pathogenesis of cholestatic hepatitis C
Volume 50, Issue 1, Pages 4-6 (January 2009)
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Outcomes in liver transplantation: Does sex matter?
Volume 60, Issue 6, Pages (June 2014)
Presentation transcript:

Non-invasive diagnosis of non-alcoholic fatty liver disease Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal  Mariana V. Machado, Helena Cortez-Pinto  Journal of Hepatology  Volume 58, Issue 5, Pages 1007-1019 (May 2013) DOI: 10.1016/j.jhep.2012.11.021 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Algorithm for decision: when to perform liver biopsy. The most validated methods are used in this algorithm, namely NAFLD Fibrosis Score and FibroScan® for the evaluation of fibrosis and CK18 fragments for the evaluation of NASH. The most significant prognostic factor is the fibrosis severity, hence is the first one to be screened. If there is clinical evidence of liver cirrhosis, and there is no doubt in terms of the aetiology of liver disease, no further assessment is needed. If NAFLD Fibrosis Score suggests advanced fibrosis, more than 90% of the patients will have advanced fibrosis, and it is essential to exclude cirrhosis, which would tremendously change the management, and we would recommend a liver biopsy. If, on the other hand, the NAFLD Fibrosis Score suggests low probability for advanced fibrosis, this can be excluded with a high confidence since it presents a 93% NPV. It could still be important to exclude the presence of NASH for prognosis purposes. If CK18 is available and it does not suggest NASH, we could be confident and maintain the patient in follow-up. On the other hand, if it suggests NASH, it should be confirmed by liver biopsy, since it will be a false positive in 14% of the patients. In the patients unclassified for NAFLD Fibrosis Score, FibroScan® can be useful, with the need to confirm cirrhosis with liver biopsy if it suggests advanced fibrosis. Journal of Hepatology 2013 58, 1007-1019DOI: (10.1016/j.jhep.2012.11.021) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2013 58, 1007-1019DOI: (10. 1016/j. jhep. 2012 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions